» Articles » PMID: 32561749

A Clinically and Genomically Annotated Nerve Sheath Tumor Biospecimen Repository

Abstract

Nerve sheath tumors occur as a heterogeneous group of neoplasms in patients with neurofibromatosis type 1 (NF1). The malignant form represents the most common cause of death in people with NF1, and even when benign, these tumors can result in significant disfigurement, neurologic dysfunction, and a range of profound symptoms. Lack of human tissue across the peripheral nerve tumors common in NF1 has been a major limitation in the development of new therapies. To address this unmet need, we have created an annotated collection of patient tumor samples, patient-derived cell lines, and patient-derived xenografts, and carried out high-throughput genomic and transcriptomic characterization to serve as a resource for further biologic and preclinical therapeutic studies. In this work, we release genomic and transcriptomic datasets comprised of 55 tumor samples derived from 23 individuals, complete with clinical annotation. All data are publicly available through the NF Data Portal and at http://synapse.org/jhubiobank.

Citing Articles

Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells.

Longakit A, Urtatiz O, Luty A, Zhang C, Hess C, Yoo A Cancer Res Commun. 2025; 5(2):209-225.

PMID: 39804140 PMC: 11788999. DOI: 10.1158/2767-9764.CRC-24-0386.


Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1.

Lucas C, Gross A, Romo C, Dehner C, Lazar A, Miettinen M Neuro Oncol. 2024; 27(3):616-624.

PMID: 39500722 PMC: 11889724. DOI: 10.1093/neuonc/noae235.


Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.

Cannizzaro I, Treccani M, Taiani A, Ambrosini E, Busciglio S, Cesarini S Int J Mol Sci. 2024; 25(19).

PMID: 39409151 PMC: 11476461. DOI: 10.3390/ijms251910822.


Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.

Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A Clin Cancer Res. 2024; 30(23):5459-5472.

PMID: 39321200 PMC: 11866061. DOI: 10.1158/1078-0432.CCR-24-1454.


A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.

Nguyen H, Kohl E, Bade J, Eng S, Tosevska A, Al Shihabi A Cell Rep Methods. 2024; 4(5):100772.

PMID: 38744290 PMC: 11133839. DOI: 10.1016/j.crmeth.2024.100772.


References
1.
Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

2.
Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

3.
Le L, Parada L . Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007; 26(32):4609-16. PMC: 2760340. DOI: 10.1038/sj.onc.1210261. View

4.
Allaway R, La Rosa S, Verma S, Mangravite L, Guinney J, Blakeley J . Engaging a community to enable disease-centric data sharing with the NF Data Portal. Sci Data. 2019; 6(1):319. PMC: 6910996. DOI: 10.1038/s41597-019-0317-x. View

5.
Gosline S, Weinberg H, Knight P, Yu T, Guo X, Prasad N . A high-throughput molecular data resource for cutaneous neurofibromas. Sci Data. 2017; 4:170045. PMC: 5387919. DOI: 10.1038/sdata.2017.45. View